Persistence, Adherence, and Switching to Higher-Cost Therapy in Patients with Multiple Sclerosis Initiating Oral Disease-Modifying Therapies: A Retrospective Real-World Study.

Lita Araujo Svend Sparre GeertsenAllen AmedumeKeiko HiguchiJanneke van Wingerden

Published in: Neurology and therapy (2022)

Patients newly initiated on teriflunomide and fingolimod had better real-world persistence and adherence at 6 and 12 months, and longer time to switch to higher-cost therapies, than patients on dimethyl fumarate or diroximel fumarate.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
stem cells
metabolic syndrome
skeletal muscle
cell therapy